AD 104 - AmyriAD
Alternative Names: AD-104 - AmyriADLatest Information Update: 16 Mar 2022
At a glance
- Originator AmyriAD
- Class Antidementias; Nootropics; Small molecules
- Mechanism of Action T-type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 15 Feb 2022 Preclinical trials in Alzheimer's disease in USA (unspecified route) (AmyriAD pipeline; February 2022)